Long-term administration of tenofovir or emtricitabine to pregnant rats; Effect on Abcb1a, Abcb1b and Abcg2 expression in the placenta and in maternal and fetal organs

Journal of Pharmacy and Pharmacology

Volumn 68, Issue 1, 2016, Pages 84-92

  Cerveny, Lukas ^a   Neumanova, Zuzana ^a   Karbanova, Sara ^a   Havlova, Ivana ^a   Staud, Frantisek ^a  

^a Charles University in Prague Faculty of Pharmacy   (Czech Republic)

Author keywords

ABC transporters; drug interactions; emtricitabine; pregnancy; tenofovir

Indexed keywords

BREAST CANCER RESISTANCE PROTEIN; EMTRICITABINE; MESSENGER RNA; MULTIDRUG RESISTANCE PROTEIN 1; PROTEIN ABCB1A; PROTEIN ABCB1B; SODIUM CHLORIDE; TENOFOVIR; UNCLASSIFIED DRUG; ABC TRANSPORTER; ABCG2 PROTEIN, RAT; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN 3;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; BIRTH WEIGHT; BRAIN TISSUE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG SAFETY; FEMALE; FETOPLACENTAL UNIT; FETUS; GENE EXPRESSION; GESTATIONAL AGE; INTESTINE; KIDNEY PARENCHYMA; LIVER; LONG TERM CARE; NEWBORN; NONHUMAN; PLACENTA WEIGHT; PREGNANCY; PROTEIN ANALYSIS; PROTEIN EXPRESSION; RAT; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SINGLE DRUG DOSE; TREATMENT DURATION; WISTAR RAT; ANIMAL; DRUG EFFECTS; METABOLISM; PLACENTA;

ANIMALS; ATP BINDING CASSETTE TRANSPORTER, SUB-FAMILY G, MEMBER 2; ATP-BINDING CASSETTE TRANSPORTERS; EMTRICITABINE; FEMALE; FETUS; P-GLYCOPROTEINS; PLACENTA; PREGNANCY; RATS; RATS, WISTAR; TENOFOVIR;

EID: 84956594370     PISSN: 00223573     EISSN: 20427158     Source Type: Journal    
DOI: 10.1111/jphp.12495     Document Type: Article

References (53)

1. Townsend D, et al,. First HAART in HIV-infected patients with high viral load: value of HIV RNA levels at 12 weeks to predict virologic outcome. J Int Assoc Physicians AIDS Care (Chic) 2009; 8: 314-317.
2. Tubiana R, et al,. Factors associated with mother-to-child transmission of HIV-1 despite a maternal viral load <500 copies/ml at delivery: a case-control study nested in the French perinatal cohort (EPF-ANRS CO1). Clin Infect Dis 2010; 50: 585-596.
3. Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission. Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV Transmission in the United States. 2014. Available at http://aidsinfo.nih.gov/contentfiles/lvguidelines/PerinatalGL.pdf. Accessed March 10 2015.
4. WHO. Use of Antiretroviral Drugs for Treating Pregnant Women and Preventing HIV Infections in Infants. Programmatic update WHO/HIV/2012.6. Available at http://whqlibdoc.who.int/hq/2012/WHO-HIV-2012.6-eng.pdf?ua=1. Accessed March 10, 2015.
5. Colbers AP, et al,. The pharmacokinetics, safety and efficacy of tenofovir and emtricitabine in HIV-1-infected pregnant women. AIDS 2013; 27: 739-748.
6. Siberry GK, et al,. Safety of tenofovir use during pregnancy: early growth outcomes in HIV-exposed uninfected infants. AIDS 2012; 26: 1151-1159.
7. Gois PH, et al,. Tenofovir during pregnancy in rats: a novel pathway for programmed hypertension in the offspring. J Antimicrob Chemother 2015; 70: 1094-1105.
8. Tarantal AF, et al,. Fetal and maternal outcome after administration of tenofovir to gravid rhesus monkeys (Macaca mulatta). J Acquir Immune Defic Syndr 2002; 29: 207-220.
9. Kis O, et al,. The complexities of antiretroviral drug-drug interactions: role of ABC and SLC transporters. Trends Pharmacol Sci 2010; 31: 22-35.
10. Neumanova Z, et al,. Interactions of tenofovir and tenofovir disoproxil fumarate with drug efflux transporters ABCB1, ABCG2, and ABCC2; role in transport across the placenta. AIDS 2014; 28: 9-17.
11. Tong L, et al,. Effects of human immunodeficiency virus protease inhibitors on the intestinal absorption of tenofovir disoproxil fumarate in vitro. Antimicrob Agents Chemother 2007; 51: 3498-3504.
12. Schinkel AH, Jonker JW,. Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview. Adv Drug Deliv Rev 2003; 55: 3-29.
13. Staud F, et al,. Pharmacotherapy in pregnancy; effect of ABC and SLC transporters on drug transport across the placenta and fetal drug exposure. J Drug Target 2012; 20: 736-763.
14. Ek CJ, et al,. Efflux mechanisms at the developing brain barriers: ABC-transporters in the fetal and postnatal rat. Toxicol Lett 2010; 197: 51-59.
15. Cygalova L, et al,. Role of breast cancer resistance protein (Bcrp/Abcg2) in fetal protection during gestation in rat. Toxicol Lett 2008; 178: 176-180.
16. Ray AS, et al,. Mechanism of active renal tubular efflux of tenofovir. Antimicrob Agents Chemother 2006; 50: 3297-3304.
17. Storch CH, et al,. Comparison of the inhibitory activity of anti-HIV drugs on P-glycoprotein. Biochem Pharmacol 2007; 73: 1573-1581.
18. Weiss J, et al,. Modulation of human BCRP (ABCG2) activity by anti-HIV drugs. J Antimicrob Chemother 2007; 59: 238-245.
19. Bousquet L, et al,. Combination of tenofovir and emtricitabine plus efavirenz: in vitro modulation of ABC transporter and intracellular drug accumulation. Antimicrob Agents Chemother 2009; 53: 896-902.
20. Svard J, et al,. Nuclear receptor-mediated induction of CYP450 by antiretrovirals: functional consequences of NR1I2 (PXR) polymorphisms and differential prevalence in whites and sub-Saharan Africans. J Acquir Immune Defic Syndr 2010; 55: 536-549.
21. Weiss J, et al,. Comparison of the induction of P-glycoprotein activity by nucleotide, nucleoside, and non-nucleoside reverse transcriptase inhibitors. Eur J Pharmacol 2008; 579: 104-109.
22. Flynn PM, et al,. Pharmacokinetics and safety of single-dose tenofovir disoproxil fumarate and emtricitabine in HIV-1-infected pregnant women and their infants. Antimicrob Agents Chemother 2011; 55: 5914-5922.
23. Barker DJ, et al,. Fetal and placental size and risk of hypertension in adult life. BMJ 1990; 301: 259-262.
24. Godfrey K, Robinson S,. Maternal nutrition, placental growth and fetal programming. Proc Nutr Soc 1998; 57: 105-111.
25. Hemachandra AH, et al,. The association between intrauterine growth restriction in the full-term infant and high blood pressure at age 7 years: results from the Collaborative Perinatal Project. Int J Epidemiol 2006; 35: 871-877.
26. Lau C, et al,. Fetal programming of adult disease: implications for prenatal care. Obstet Gynecol 2011; 117: 978-985.
27. Risnes KR, et al,. Placental weight relative to birth weight and long-term cardiovascular mortality: findings from a cohort of 31,307 men and women. Am J Epidemiol 2009; 170: 622-631.
28. Radilova H, et al,. COX-1 is coupled with mPGES-1 and ABCC4 in human cervix cancer cells. Mol Cell Biochem 2009; 330: 131-140.
29. Vandesompele J, et al,. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol 2002; 3: RESEARCH0034.
30. Huggett J, et al,. Real-time RT-PCR normalisation; strategies and considerations. Genes Immun 2005; 6: 279-284.
31. Pospechova K, et al,. Expression and activity of vitamin D receptor in the human placenta and in choriocarcinoma BeWo and JEG-3 cell lines. Mol Cell Endocrinol 2009; 299: 178-187.
32. Livak KJ, Schmittgen TD,. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 2001; 25: 402-408.
33. Zorrilla EP, et al,. Leukocytes and organ-nonspecific autoantibodies in schizophrenics and their siblings: markers of vulnerability or disease? Biol Psychiatry 1996; 40: 825-833.
34. Group TEAS et al. Maternal and nenonatal tenofovir and emtricitabine to prevent vertical transmission of HIV-1: tolerance and resistance. AIDS 2010; 24: 2481-2488.
35. Nurutdinova D, et al,. Adverse effects of tenofovir use in HIV-infected pregnant women and their infants. Ann Pharmacother 2008; 42: 1581-1585.
36. Baroncelli S, et al,. Antiretroviral treatment in pregnancy: a six-year perspective on recent trends in prescription patterns, viral load suppression, and pregnancy outcomes. AIDS Patient Care STDS 2009; 23: 513-520.
37. de Zwart L, et al,. The ontogeny of drug metabolizing enzymes and transporters in the rat. Reprod Toxicol 2008; 26: 220-230.
38. Hartung T, Daston G,. Are in vitro tests suitable for regulatory use? Toxicol Sci 2009; 111: 233-237.
39. Turner PV, et al,. Administration of substances to laboratory animals: routes of administration and factors to consider. J Am Assoc Lab Anim Sci 2011; 50: 600-613.
40. Anzenbacherova E, et al,. In vivo study of the effect of antiviral acyclic nucleotide phosphonate (R)-9-[2-(phosphonomethoxy)propyl]adenine (PMPA, tenofovir) and its prodrug tenofovir disoproxil fumarate on rat microsomal cytochrome P450. Physiol Res 2008; 57: 761-767.
41. Rosati A, et al,. Physiological regulation of P-glycoprotein, MRP1, MRP2 and cytochrome P450 3A2 during rat ontogeny. Dev Growth Differ 2003; 45: 377-387.
42. Alcorn J, McNamara PJ,. Ontogeny of hepatic and renal systemic clearance pathways in infants: part I. Clin Pharmacokinet 2002; 41: 959-998.
43. Cui YJ, et al,. Tissue distribution, gender-divergent expression, ontogeny, and chemical induction of multidrug resistance transporter genes (Mdr1a, Mdr1b, Mdr2) in mice. Drug Metab Dispos 2009; 37: 203-210.
44. Mooij MG, et al,. Ontogeny of human hepatic and intestinal transporter gene expression during childhood: age matters. Drug Metab Dispos 2014; 42: 1268-1274.
45. Maier T, et al,. Correlation of mRNA and protein in complex biological samples. FEBS Lett 2009; 583: 3966-3973.
46. Aleman C, et al,. P-glycoprotein, expressed in multidrug resistant cells, is not responsible for alterations in membrane fluidity or membrane potential. Cancer Res 2003; 63: 3084-3091.
47. Imai Y, et al,. Estrogen-mediated post transcriptional down-regulation of breast cancer resistance protein/ABCG2. Cancer Res 2005; 65: 596-604.
48. Schwanhausser B, et al,. Global quantification of mammalian gene expression control. Nature 2011; 473: 337-342.
49. Haslam IS, et al,. Rifampin and digoxin induction of MDR1 expression and function in human intestinal (T84) epithelial cells. Br J Pharmacol 2008; 154: 246-255.
50. Oda K, et al,. Estrogen receptor alpha induction by mitoxantrone increases Abcg2 expression in placental trophoblast cells. J Pharm Sci 2013; 102: 3364-3372.
51. Eskild A, et al,. Placental weight and placental weight to birthweight ratio in relation to Apgar score at birth: a population study of 522 360 singleton pregnancies. Acta Obstet Gynecol Scand 2014; 93: 1302-1308.
52. de Souza J, et al,. Comparison of bidirectional lamivudine and zidovudine transport using MDCK, MDCK-MDR1, and Caco-2 cell monolayers. J Pharm Sci 2009; 98: 4413-4419.
53. Giri N, et al,. Investigation of the role of breast cancer resistance protein (Bcrp/Abcg2) on pharmacokinetics and central nervous system penetration of abacavir and zidovudine in the mouse. Drug Metab Dispos 2008; 36: 1476-1484.